Fcmalt Injection contains Ferric Carboxymaltose (50mg/ml), an intravenous iron preparation used to treat iron deficiency anemia, particularly when oral iron therapy is ineffective or not feasible. It is indicated for patients with chronic kidney disease, postpartum anemia, or those undergoing chemotherapy who require rapid replenishment of iron stores. Ferric Carboxymaltose works by delivering iron directly into the bloodstream, allowing for quick correction of iron deficiency and improvement in hemoglobin levels. This injection provides a controlled release of iron, minimizing the risk of free iron toxicity and allowing for larger single doses compared to traditional iron formulations. Fcmalt Injection is administered by healthcare professionals via slow intravenous infusion or injection, with dosage and frequency tailored according to the patient’s iron deficit and clinical condition. Common side effects may include mild injection site reactions, headache, dizziness, nausea, or hypersensitivity reactions, though serious adverse events are rare. It is contraindicated in patients with known hypersensitivity to Ferric Carboxymaltose or any of its components, and caution is advised in individuals with iron overload disorders. Proper patient monitoring during and after administration is essential to ensure safety and efficacy.